Pipeline - Trovagene

Providing New Treatment Options Across a
Wide Array of Cancers

Demonstrated synergy of onvansertib in combination with already
approved chemotherapies and targeted therapeutics

Pipeline within a Molecule

We are developing onvansertib as part of a combination regimen across a variety of cancers and integrating a predictive clinical biomarker strategy to identify patients who are most likely to respond to treatment. The opportunity to bring new treatment options to patients in indications where there is a high medical need we believe presents significant market opportunities.

Phase 1
Phase 2
Acute Myeloid Leukemia – Orphan Drug Designation in the U.S. and Europe
Phase 1b/2 trial in combination with low-dose cytarabine (LDAC) or Decitabine
Leukemias & Lymphomas
Metastatic Castration-Resistant Prostate (CRPC)
Phase 2 trial in combination with Zytiga® (abiraterone acetate)/prednisone
Colorectal (CRC)
Phase 1b/2 trial in combination with FOLFIRI + Avastin®
Phase 1b/2 trial ready
Phase 1b/2 trial ready
Phase 1b/2 trial ready
Solid Tumor Cancers
Small Cell Lung
Phase 1b/2 trial ready
A Phase 1 trial has been completed in advanced or metastatic solid tumor cancers, including colorectal, lung, and ovarian, and published in Investigational New Drugs in 2017

Recent News

Aug 8, 2019

Trovagene Announces Second Quarter 2019 Results and Highlights

SAN DIEGO, Aug. 8, 2019 /PRNewswire/ — Trovagene, Inc. (Nasdaq: TROV), a clinical-stage Precision Cancer Medicine™ company, developing drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and
solid tumor cancers, today announced company highlights and financial results for the second quarter ended June 30, 2019.

Jul 22, 2019

ESMO Accepts Trovagene AML Clinical Trial Abstract for Oral Presentation

Acute Myeloid Leukemia (AML) clinical trial data to be presented in an oral presentation.

Jul 15, 2019

Trovagene Commences Non-Deal Investor Roadshow

Management team to meet with investment institutions, analysts and shareholders in NYC to provide an overview of the Company and its advancing clinical development of onvansertib.